Observational Study on Low-Flow Extracorporeal Carbon Dioxide Removal ECCO2R Safety and Effectiveness in Adults with Respiratory Failure in ICU

What this Trial Is About

This research aims to understand the use of low-flow extracorporeal carbon dioxide removal ECCO2R therapy in patients with respiratory failure admitted to intensive care units ICUs. The study will look at how patients are selected for this therapy, the technical details of its management, and the clinical outcomes including any adverse events. This observational study is conducted by reviewing past data collected as part of routine care and is sponsored by Hong Kong University. The study focuses on patients who received ECCO2R support in specific ICUs between January 2022 and June 2024. It does not involve any new treatments or interventions but reviews existing clinical practices and patient results related to low-flow ECCO2R therapy. Researchers will gather detailed information about patient characteristics and the therapys application during this period. Participants clinical data will be analyzed retrospectively from November 2024 to September 2026 to assess around 60 patients with respiratory failure. The study includes reviewing clinical characteristics, patient outcomes, and any complications associated with ECCO2R therapy. Since this is an observational study, there is no active treatment or follow-up required from participants, and data is collected from past records to improve understanding of ECCO2R use in ICUs.

Retrospective Cohort Study of Low-Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) System: Evaluating ECCO2R's Efficacy and Safety in Participants With Respiratory Failure